We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.29 | 0.66% | 43.99 | 44.33 | 43.685 | 43.93 | 12,104,157 | 01:00:00 |
From Nov 2023 to May 2024
10:45 ET -- Bristol Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Bristol Myers Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Under the terms, Bristol would pay $330 a share in cash for Karuna and its experimental schizophrenia drug now up for U.S. government approval. Bristol expects the deal, which includes $1.3 billion in cash that Karuna has on hand, would close in the first half of next year. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)
(END) Dow Jones Newswires
December 22, 2023 11:00 ET (16:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
